The phosphoinositide-3 kinase (PI-3K)/AKT cell survival pathway is an important pathway activated by EGFR signaling. Here we show, that in addition to previously described critical components of this ...
For the purpose of clarity, the signaling pathways can be discussed in isolation. However, in reality there is considerable cross-talk between pathways, with parallel or upstream input from other ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi). This is an ASCO ...
KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...
Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.
Human epidermal growth factor receptor 2 (HER2) is a membrane-spanning receptor that belongs to the family of epidermal growth factor receptor tyrosine kinases (EGFR TKIs), which consists of three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback